BioAge Labs, Inc. (BIOA) Q3 Net Loss Widens To $33.5M; Cash Runway Through 2029

BioAge Labs reported a Q3 2026 net loss of $33.5M, up from $20.2M in Q3 2025. The company has $352.3M in cash, expected to last through 2029. BioAge is investing in its lead program, QUELL-CV, with topline data anticipated in Q4 2026.

Original reporting
Published Nov 5, 2026, 9:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 9:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
BioAge Labs, Inc. (BIOA) Q3 Net Loss Widens To $33.5M; Cash Runway Through 2029 — source image
Decision brief

The 30-second read

$BIOABearishMed
01

Why it matters

The earnings miss may trigger short‑term price pressure, while the cash balance supports continued R&D and upcoming trial milestones.

02

Market read

Earnings release provides fresh data for traders; the loss widens but cash runway offers a defensive cushion.

03

What to watch

Upcoming QUELL‑CV and QUELL‑DME trial readouts could materially change the risk/reward profile.

Relevance 7/10Novelty 8/10Timing: post-market today

Background

BioAge Labs reported its Q3 2026 earnings, showing a larger loss than the prior year but a sizable cash position.

Company-level read

Ticker impact

$BIOABearishHigh confidence
Context

Q3 2026 net loss widens to $33.5M and cash balance of $352.3M disclosed, new earnings data for BioAge Labs.

Expected impact

likely modest downside as investors digest larger loss, tempered by ample liquidity

Evidence & confidence

Earnings surprise is negative; cash cushion reduces risk of immediate financing pressure.

Market effects

Highlights continued cash burn in clinical‑stage biotech, may prompt sector peers to emphasize runway guidance.

Limited to US biotech investors; no broader regional effect.

Minimal global impact beyond biotech niche.

Counterpoint

The cash runway to 2029 could be seen as a runway for upcoming Phase 2 data, offering upside potential despite the loss.

Key entities

  • BioAge Labs, Inc.

    Clinical‑stage biotech developing aging therapeutics.

Related articles

$BIOAMedAI 8/10

Five-year data of continuous Leqembi® treatment show increasing benefit over time

BioArctic's partner Eisai presented five-year data from the Clarity AD study, showing continuous Leqembi treatment in early Alzheimer's disease increased clinical benefits over time. 62% of patients treated early showed cognitive improvement. Leqembi reduced cognitive decline by 2.05 points after five years compared to historic data. Eisai and BioArctic collaborate on Leqembi's development and commercialization.

$BIOAMed

BioAge Labs 3Q 2026: Revenue $298K, EPS ($0.73) — 10-Q Summary

BioAge Labs (BIOA) reported 3Q 2026 revenue of $298K, down 85% YoY, and a net loss of $33.5M, up 66% YoY. The decline was due to a $1.7M adjustment in Novartis collaboration revenue. R&D costs rose 63% to $30.2M, driven by BGE-102 trial and manufacturing expenses. The company completed QUELL-CV enrollment and expects topline data in 4Q 2026.

$BIOAMed

BioAge Labs Reports Third Quarter 2026 Financial Results and Provides Business Updates

BioAge Labs, Inc. (BIOA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 BioAge Labs Reports Third Quarter 2026 Financial Results and Provides Business Updates First participant dosed in QUELL-DME, a Phase 2 trial of BGE-102, a potential best-in-class oral NLRP3 inhibitor, in diabetic macular edema; topline results anticipated in the seco

$BIOAMed

About $352 million in cash and securities could fund BioAge's operations through 2029

BioAge Labs (NASDAQ: BIOA) reported $352M in cash and securities for operations through 2029. It dosed the first participant in a Phase 2 trial for BGE-102 in diabetic macular edema, with results expected in 2H 2027. The QUELL-CV Phase 2 trial for BGE-102 in obesity completed enrollment, with data due in 4Q 2026. The company aims to file an IND for its APJ agonist program by year-end 2026. BioAge also updated its collaborations with Novartis, Lilly, and Deep Origin.

$BIOAMedAI 8/10

BioAge Labs, Inc. recently announced that the first participant has been dosed in QUELL-DME, a randomized, controlled Phase 2 trial evaluating once-daily…

BioAge Labs, Inc. (BIOA) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events BioAge Labs, Inc. (the “ Company ”) recently announced that the first participant has been dosed in QUELL-DME, a randomized, controlled Phase 2 trial evaluating once-daily oral BGE-102, an NLRP3 inhibitor, in adults with diabetic macular edema (“ DME ”), an